Repare Therapeutics Q3 EPS $(0.45) Beats $(0.86) Estimate, Sales $2.16M Miss $6.31M Estimate
Portfolio Pulse from Benzinga Newsdesk
Repare Therapeutics (NASDAQ:RPTX) reported Q3 losses of $(0.45) per share, beating the analyst consensus estimate of $(0.86) by 47.67%. However, the company's quarterly sales of $2.16 million missed the analyst consensus estimate of $6.31 million by 65.78%. This represents a 98.08% decrease over sales from the same period last year.
November 09, 2023 | 12:47 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Repare Therapeutics reported better than expected Q3 EPS but missed on sales. This could lead to mixed market reactions.
Repare Therapeutics reported a better than expected EPS, which is a positive signal for investors. However, the company missed on sales, which is a negative signal. These mixed results could lead to uncertainty and mixed reactions in the market.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100